Patents by Inventor Daniel Yongwon LEE

Daniel Yongwon LEE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TARGETING MOIETY-DRUG GRAFTED IMMUNE CELL COMPOSITIONS AND METHODS OF USE
    Publication number: 20250043023
    Abstract: Surface-engineered immune cells, such as natural killer cells, grafted with targeting moiety-drug complexes. The present invention combines chemotherapy and immunotherapy by engineering the immune cells to target specific tumor cells through antigen recognition and deliver potent chemotherapeutic agents, thereby destroying the tumor cells. The surface-engineered immune cells may be prepared using a one-step method. The present invention also provides kits for preparing the surface-engineered immune cells.
    Type: Application
    Filed: October 22, 2024
    Publication date: February 6, 2025
    Inventors: Youngwook WON, David A. BULL, Daniel Yongwon LEE
  • Targeting moiety-drug grafted immune cell compositions and methods of use
    Patent number: 12180300
    Abstract: Surface-engineered immune cells, such as natural killer cells, grafted with targeting moiety-drug complexes. The present invention combines chemotherapy and immunotherapy by engineering the immune cells to target specific tumor cells through antigen recognition and deliver potent chemotherapeutic agents, thereby destroying the tumor cells. The surface-engineered immune cells may be prepared using a one-step method. The present invention also provides kits for preparing the surface-engineered immune cells.
    Type: Grant
    Filed: September 20, 2019
    Date of Patent: December 31, 2024
    Assignees: ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA, UNIVERSITY OF UTAH RESEARCH FOUNDATION
    Inventors: Youngwook Won, David A. Bull, Daniel Yongwon Lee
  • TARGETING MOIETY-DRUG GRAFTED IMMUNE CELL COMPOSITIONS AND METHODS OF USE
    Publication number: 20210353768
    Abstract: Surface-engineered immune cells, such as natural killer cells, grafted with targeting moiety-drug complexes. The present invention combines chemotherapy and immunotherapy by engineering the immune cells to target specific tumor cells through antigen recognition and deliver potent chemotherapeutic agents, thereby destroying the tumor cells. The surface-engineered immune cells may be prepared using a one-step method. The present invention also provides kits for preparing the surface-engineered immune cells.
    Type: Application
    Filed: September 20, 2019
    Publication date: November 18, 2021
    Inventors: Youngwook WON, David A. BULL, Daniel Yongwon LEE